Registry of IgA Nephropathy in Chinese Children

Summary

This study tries to identify the safe and effective treatment option for IgA nephropathy in children. Investigators will perform prospective registration study among 25 pediatric nephrology medical centers in China.

Conditions

• IgA Nephropathy
• Proteinuria in Nephrotic Range
• Immunosuppressive Treatment

Interventions

DRUG

Corticosteroid

DRUG

Cyclophosphamide

DRUG

Mycophenolate mofetil

DRUG

Dipyridamole

DRUG

ACE Inhibitor or Angiotensin receptor antagonist

Sponsors & Collaborators

• Nanjing PLA General Hospital

  collaborator OTHER

• Beijing Children's Hospital

  collaborator OTHER

• Central South University

  collaborator OTHER

• The Children's Hospital of Zhejiang University School of Medicine

  collaborator OTHER

• First Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Hunan Children's Hospital

  collaborator OTHER_GOV

• Shanghai Children's Hospital

  collaborator OTHER

• Nanjing Children's Hospital

  collaborator OTHER

• Children's Hospital of Chongqing Medical University

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Fuzhou General Hospital

  collaborator OTHER

• Second Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Children's Hospital of Hebei Province

  collaborator OTHER

• Guangzhou Women and Children's Medical Center

  collaborator OTHER

• Jiangxi Province Children's Hospital

  collaborator OTHER

• Guangzhou First People's Hospital

  collaborator OTHER

• Xian Children's Hospital

  collaborator OTHER_GOV

• Capital Institute of Pediatrics, China

  collaborator OTHER

• The First Hospital of Jilin University

  collaborator OTHER

• Wuhan Women and Children's Medical Center

  collaborator OTHER

• Tianjin Children's Hospital

  collaborator OTHER

• Chengdu Women's and Children's Central Hospital

  collaborator OTHER

• The First People's Hospital of Yunnan

  collaborator OTHER

• Peking University First Hospital

  lead OTHER

Principal Investigators

• Jie Ding, Prof. · Peking University First Hospital

Eligibility

Min Age

1 Month

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-01-31

Primary Completion

2024-12-31

Completion

2024-12-31

Countries

• China

Study Locations